Church & Dwight Long-Term Value Investment Analysis

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it enlarging a slice of an existing pie, or creating an entirely new market?5/10

  A

  Bottom line up front: what CHD does is "grab a higher-quality slice within a mature, slowly growing large pie," rather than creating an entirely new market. Its ceiling is set by two things—the penetration depth of existing household and personal-care categories, and how large a share of high-growth "fast-moving consumer subcategories" it can fold onto its platform through M&A; this is a real but limited slope, not the kind of brand-new market Baillie Gifford loves most—"from 0 to 1, a tenfold ramp over ten years."

  First, the nature of the market it operates in. In its 2025 10-K the company states plainly that the U.S. consumer-products market "is already mature, commonly characterized by high household penetration" (U.S. markets for consumer products are considered mature and commonly characterized by high household penetration), and that about 82% of 2025 sales came from the U.S. market. The flagship ARM & HAMMER brand's baking soda entered American kitchens as early as 1846 and is already at national-level penetration. In other words, core categories such as laundry, cat litter, oral care, and deodorizing have long-stable demand but a pie that will not grow quickly—which is precisely why the company's 2025 organic growth was only 0.7% (of which 130bp came from the drag of the divested vitamins business). This is not a "the ceiling is far away" story.

  But the ceiling is not a wall either; the company has two clear paths to enlarge the pie, both of which are "enlarging the existing pie" rather than "opening a new market": one is to extend existing brands into adjacent categories (ARM & HAMMER extending from baking soda into laundry, cat litter, oral care, and deodorizing), relying on reuse of the same brand equity; the other is the three growth pillars the company spells out in its 10-K—growing oral care from $1 billion to $1.5 billion (via TheraBreath), and growing the international business from $1 billion to $2 billion. These all raise penetration and share within already-existing large markets—clear, executable goals, but on the order of "doubling" rather than "a tenfold jump."

  The only expansion with a hint of "creating a new market" is M&A-style expansion: Touchland remade what was originally a marginal hand-sanitizer category into a design-forward, high-repeat personal-care product (TTM net sales of about $130 million, the fastest-growing brand in the category, and No. 2 in the category). Such targets are indeed "redefining" a small category, but for a company with annual sales of $6.2 billion, even a single new category doubling is only a marginal increment—not enough to support an order-of-magnitude leap in the overall ceiling.

  Honest conclusion: measured by Baillie Gifford's "market ceiling" yardstick, CHD falls into the lower-scoring category—the slope is real, sustainable, and can be delivered by management step by step, but what it does is share and category upgrades within an existing market, lacking the exponential imaginative space of "a brand-new market from nothing." For long-term value investors this is a strength (high certainty); for growth investors seeking a five-fold return over ten years it is a hard constraint (upside capped by market size).

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Is growth driven mainly by volume, price, or new businesses?3/10

  A

  Bottom line up front: almost impossible. Doubling CHD's revenue within five years would require about 15% compound annual growth; but over the past six years (2019–2025) the company's revenue CAGR was only about 6%, and management's own 2026 organic-growth guidance is just 3%–4%. On Baillie Gifford's "double in five years" gate, CHD clearly fails. Structurally, it is a business driven mainly by volume, with price as support and M&A adding increments, not a high-growth stock ramping on a single engine.

  First, lay out the numbers. The company's full-year 2025 net sales were $6.203 billion, up 1.6% year over year, with organic sales up only 0.7%—note that this 0.7% still includes about 130bp of drag from the exited vitamins business; excluding it, about 1.8%. The 2026 guidance is organic +3%–4%, but reported sales are set to decline by about 0.5%–1.5%, because the businesses exited in 2025 took with them about $400 million in revenue. For a company whose reported revenue is still shrinking due to portfolio trimming, talk of doubling in five years is unrealistic.

  Next, what drives growth, broken into three parts:

  • Volume: the main engine. Management explicitly defines the 3%–4% organic growth in 2026 as "volume driven," and stresses that new-product launches will contribute about half of organic growth. This is healthy growth quality (driven by real demand rather than forced price increases), but naturally moderate.
  • Price/mix: a support. The company has repeatedly emphasized using "surgical pricing" to offset costs and tariffs, rather than driving revenue through across-the-board price increases; in mature everyday goods, aggressive pricing directly loses share, so the price leg has limited room.
  • New businesses/M&A: an incremental supplement rather than a doubling lever. Touchland (acquisition price of $700 million plus up to $180 million in earnout, TTM sales of about $130 million, with double-digit growth expected in 2025 and 2026) and the TheraBreath-related expansion newly acquired in January 2026 are typical of the company's "small, frequent bolt-on M&A." But a single acquisition's scale relative to $6.2 billion in revenue is a single-digit-percent increment; to double via M&A in five years would mean acquiring the equivalent of half of itself—inconsistent with the company's disciplined M&A style of "strict standards, focus on fast-moving consumer goods."

  Why do I still treat it as a good business, just not a high-growth stock? Because its growth, though slow, is real and sustainable, with a strong ability to convert into cash (2025 operating cash flow of $1.215 billion, up 5.1% year over year). The "key assumptions" the report gives are only that core brands sustain long-term organic/owner-earnings growth of 3%–5% (per the report), which precisely shows that even the bulls do not treat doubling as the base case.

  Honest conclusion: doubling revenue in five years is unrealistic; a reasonable expectation is cumulative growth of about 15%–25% over five years (mid-single-digit annualized), driven mainly by volume, with price and M&A as support. This is fine for long-term holders who demand certainty, but for a Baillie Gifford-style screen "seeking a five-fold return over ten years," CHD is a negative on this question.

  Jun 11, 2026
• QFive years from now, what will take the baton as the next growth engine? Does this "second curve" exist today?4/10

  A

  Bottom line up front: CHD's "second curve" truly already exists today, and is visible and tangible—it is the set of "high-growth, high-repeat, strong-brand new water sources in fast-moving consumer goods" (TheraBreath, Hero, Touchland) that it is building through M&A, plus rising penetration in international and e-commerce. But to be honest: this second curve is meant to replace the natural decline of old categories and maintain overall mid-single-digit growth, not a disruptive new engine that lifts the company to a whole new growth level. It keeps CHD from becoming a stagnant old consumer stock, but will not turn it into a high-growth stock.

  Why is the second curve already real rather than pie in the sky? Because it has already landed financially and in the portfolio. The company writes its growth brands directly into its strategic pillars: growing global oral care from $1 billion to $1.5 billion (via TheraBreath), and growing the international business from $1 billion to $2 billion, and in January 2026 it completed another TheraBreath-related acquisition to reinforce this curve. Touchland is the newest and most representative new water source: a $700 million acquisition, TTM sales of about $130 million, the fastest-growing brand in its category, double-digit growth expected in 2025/2026, and about 3% accretion to cash earnings in 2026. These are not concepts on a slide deck, but assets already consolidated and already contributing growth—the list of seven power brands already includes Touchland and has replaced the divested vitamins business (the seven power brands still account for about 70% of net sales and profit).

  The "quality" of the second curve is also good: these brands are all high-repeat, strong-brand, fast-turnover personal-care/oral-care consumer products, with better unit economics than the low-margin businesses they replaced—which is why the company's 2025 adjusted gross margin reached 45.5%, up about 90bp year over year, with 2026 guidance for another expansion of about 100bp. The portfolio is migrating toward "higher quality, higher growth, lighter capital," a judgment the report gets right.

  But the "magnitude" of the second curve is its ceiling. Growing oral care from $1 billion to $1.5 billion and international from $1 billion to $2 billion adds up to a mid-term target on the order of only a few billion dollars in total; layered onto a $6.2 billion base, this corresponds to "maintaining mid-single-digit growth" rather than "building another CHD." Moreover, this curve depends heavily on continually finding, buying right, and integrating well new brands—both a capability and a risk: per the report, the large 2025 buyback looks more like a routine move than bottom-fishing at undervaluation, and if the company overpays for new targets in a high-valuation environment in the future, the second curve could instead become a source of goodwill impairment (the 2024 $357.1 million trade-name impairment of the vitamins business is a cautionary precedent).

  Honest conclusion: the second curve truly exists today, is of good quality, and is taking the baton—this is a key positive that distinguishes CHD from stagnant old consumer stocks; but its mission is "life extension and upgrade," not "exponential scaling." For long-term holders, this means the company will very likely maintain its status as a high-quality defensive asset; from the Baillie Gifford-style perspective of seeking the next steep growth curve, it is steady enough but not steep enough.

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?5/10

  A

  Bottom line up front: CHD's core moat is a combination of brand + shelf channel + scale procurement + M&A integration capability, not any single patent or network effect. Over the next three to five years, my judgment is "solid overall, rotating internally"—the company-level portfolio moat will not collapse, but it will not widen significantly either, and some single-category moats are still narrowing. In a sentence: this is "tearing down the old wall, building a new wall," not "the old wall being raised ever higher."

  First, where the moat is strong and how hard it is. On the brand side, ARM & HAMMER is a national-level flagship brand, the company is a leading U.S. producer of baking soda, and the brand extends into laundry, cat litter, oral care, deodorizing, and multiple categories; its U.S. household penetration is so high that its 2024 annual report discloses it reaches about 86% of U.S. households. This penetration and mindshare are a real pricing base—supporting the company's 2025 adjusted gross margin of 45.5%, up about 90bp year over year. On the scale and channel side, the company has long been in large retail systems and has grown global online sales to 21.4% of consumer product sales in 2025, a mature omni-channel operator. On the cost and supply-chain side, the company has a degree of vertical integration in baking-soda base raw materials and has raised the qualified dual-sourcing share of direct materials to about 70%, strengthening its resilience to shocks.

  But this moat has clear boundaries and cracks that must be pointed out honestly:

  • It is not a monopoly, and its competitors are each larger. The rivals the company itself lists are giants such as P&G, Clorox, Colgate-Palmolive, and Reckitt; in most subcategories CHD is not the largest in the whole industry.
  • Private labels are directly eroding it. The 10-K states plainly: in 2025 some of the company's largest customers launched private labels competing with its products, and may continue to expand them; combined with the ongoing shift to online shopping intensifying e-commerce competition from traditional giants and digital-native new brands.
  • Single-category moats can genuinely narrow and be abandoned. The hardest evidence is the vitamins business: in 2024 a $357.1 million trade-name impairment was taken due to competition from private labels and new entrants, followed by selling it entirely at the end of 2025—for this category once listed as the "eighth power brand," the moat narrowed to the point where management chose to exit.

  How to view the moat trend over the next three to five years? My judgment is "stable but not widening": on one hand, the company is actively replenishing new water sources—adding Touchland to the seven power brands, acquiring TheraBreath to reinforce oral care, and replacing declining categories with higher-growth, stronger-brand fast-moving consumer assets (the seven power brands still account for about 70% of net sales and profit); on the other hand, retailers' bargaining power is rising rather than falling—Walmart accounts for about 23%, and the top four customers about 44% of 2025 net sales, and channel concentration is itself a sword hanging over the moat.

  Honest conclusion: the moat truly exists and converts into decent gross margin and cash flow—this is the foundation of CHD's claim to a "high-quality company" label; but it is a narrow-to-moderate moat maintained through portfolio management, not the kind that widens itself. The most likely state over the next three to five years is "holding steady, rotating," rather than "widening"—acceptable for holders who demand a margin of safety, but do not misread it as a growth story of a continuously expanding moat.

  Jun 11, 2026
• QIf its core business were disrupted, does it have the DNA to reinvent itself? How does it treat mistakes and bad news?5/10

  A

  Bottom line up front: in "facing mistakes and bad news," CHD's conduct is honest, decisive, and unsentimental—one of its most respectable management qualities. But at the level of "if the core business were disrupted, can it reinvent itself," its DNA is "constant blood-swapping through capital allocation" rather than "achieving a paradigm leap through its own R&D or technical capability." In other words, it is good at metabolizing by buying and selling brands, but lacks the kind of inner reinvention that can "rise from the ashes after the core is overturned"—fortunately, the risk of its industry being disrupted wholesale is inherently low.

  First, "how it treats mistakes and bad news"—the evidence is hard and the direction is right:

  • Admit mistakes and cut losses, without shielding them. The vitamins business is a textbook case: after private labels and new entrants narrowed the category's moat, the company first took a $357.1 million trade-name impairment in 2024 to acknowledge reality, then sold the entire VMS business at the end of 2025—for an asset it had once listed as its "eighth power brand," it exited without hesitation.
  • Proactively trim low-quality assets. Beyond vitamins, the company also exited low-margin businesses such as Flawless, Spinbrush, and Waterpik showerheads; in 2025 these exits together took away about $400 million in revenue and related stranded costs. A company willing to shrink reported revenue for the sake of portfolio quality shows that its response to "bad news" is to act rather than to whitewash.
  • Disclose bad news as it is. In its 2025 results the company directly admitted Q4 organic growth of only 0.7%, below its own guidance of about 1.5%, due to weakening category growth and declining vitamins sales, without hiding anything. This transparency is itself an expression of "treating bad news honestly."

  Next, "the DNA to reinvent itself"—the implicit premise this chained question requires to be filled in, and also a relative weakness of CHD:

  Its reinvention mechanism is portfolio blood-swapping driven by capital allocation, not self-evolution of core capabilities. The company's playbook of "selling declining categories, buying high-growth fast-moving new brands" is indeed effective—adding Touchland to the seven power brands, acquiring TheraBreath-related businesses in early 2026, and pushing oral care from $1 billion toward $1.5 billion and international from $1 billion toward $2 billion (strategic pillars in the 10-K). But this is essentially "buying the future with money," relying on the ability to continually find, buy right, and integrate well targets, not on any internal technology or platform that could rise phoenix-like after disruption. It is not platform-type or technology-driven; if its core fast-moving categories were truly overturned by some structural force (such as a channel upheaval or a cliff in consumer habits), what it could rely on would still be "buying another batch of new brands," not rebuilding itself.

  However, the damage from this weakness is greatly diminished by the nature of the industry. In CHD's household and personal-care categories, the risk of technological disruption is inherently far lower than in software or hardware—its threats come mainly from gradual channel change, private labels, and taste migration, rather than an overnight paradigm replacement. For a business "unlikely to be disrupted wholesale," lacking aggressive self-reinvention DNA is not fatal.

  Honest conclusion: on treating mistakes and bad news, CHD scores high—decisive in admitting error, proactive in cutting losses, transparent in disclosure, a real management positive; but on the tougher question of "self-reinvention after the core is disrupted," it relies on capital-allocation blood-swapping rather than inner regenerative power, and rates moderate-to-weak. Fortunately, its industry is unlikely to see the kind of disruption that requires rising from the ashes, so this weakness poses limited threat to its long-term survival.

  Jun 11, 2026
• QDoes management (especially the founders) have a long-term vision and interests deeply tied to the company? Are they willing to sacrifice current profit for five to ten years out?4/10

  A

  Bottom line up front: CHD's management is "institutionally aligned, credibly disciplined," but not the type Baillie Gifford most prefers—"founder heavily invested, fate deeply tied to the company." There is no founder here—the company has nearly 180 years of history and just completed a CEO handover in 2025, and management's shareholding is mandated by compensation rules rather than family-style large personal equity. It is willing to sacrifice current profit for the long term (proactive divestitures, increased investment), but this long-termism comes from institutional discipline, not the "put their net worth on the line" community-of-fate of a founder.

  First, let me quantify the "degree of alignment" with facts—this is CHD's core weakness on this question:

  • No founder; professional-manager governance. Per the report, Matthew Farrell retired on April 1, 2025, and Richard Dierker took over as CEO on April 2.
  • Shareholding is institutional, not heavily concentrated. Per the report, as of March 2026 the new CEO personally held about 179,702 shares, and management and directors together held about 3.75 million shares, only about 1.6% of shares outstanding. Against the company's float of about 236.7 million shares, this is a typical "salary + equity incentive" professional-manager structure, not the fate-binding of a founder who puts the vast majority of net worth into the company.
  • Alignment supplemented by rules. Per the report, the company does have fairly strict ownership requirements—the CEO must hold company stock equivalent to 6x annual salary, the CFO 3x, EVPs 2.5x—and about 89% of the CEO's target total compensation is at-risk (tied to performance), with mandatory and supplemental clawback policies already adopted. This system keeps the direction of interests broadly aligned, but "alignment forced by rules" and "a founder's natural alignment" differ in risk appetite and time horizon.

  Next, "whether it has a long-term vision and is willing to sacrifice current profit for five to ten years out"—here CHD performs clearly better:

  • Willing to proactively sacrifice current revenue for the long term. In 2025, for portfolio quality, the company divested vitamins and exited several low-margin businesses, directly taking away about $400 million in revenue and stranded costs, and reported sales are therefore set to decline in 2026—a classic move of trading short-term revenue for long-term portfolio quality.
  • Willing to increase investment for the future. The 2026 guidance explicitly states that marketing as a percentage of sales will exceed 11% and SG&A share will rise, to support Touchland, e-commerce, and international new growth—that is, proactively pressing current margins a bit to invest in the future.
  • Long-term-model oriented. The company has long held "Evergreen"-style targets and "small, frequent bolt-on M&A," pushing oral care from $1 billion toward $1.5 billion and international from $1 billion toward $2 billion (strategic pillars in the 10-K), a way of building the portfolio on a five-to-ten-year horizon.

  But capital allocation is not elegant at every step, which bears on "whether to give full hindsight credit." In 2025 the company repurchased about $900 million of stock while the market valuation was already above 30x P/E—by results, this looks more like "disciplined routine buybacks" than "buying back aggressively when clearly undervalued." This shows management is rational but not extreme; its care for shareholder value is "solid-to-good" rather than "textbook-grade."

  Honest conclusion: management is trustworthy, well-disciplined, genuinely long-term in vision, and willing to sacrifice current profit for the future—all real positives (the report's 3.5/5 is fair); but measured by Baillie Gifford's highest standard of "founder-style deep binding, tying net worth to the company's fate," CHD falls into the clearly negative category—it is an excellent professional-manager company, not a founder's all-in community of fate.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and free of reliance on harming society and regulation?5/10

  A

  Bottom line up front: if CHD disappeared tomorrow, consumers would miss it "to a moderate degree"—its brands have real mindshare on their respective shelves, but the vast majority of categories have equivalent substitutes, and life would go on without it, with no "irreplaceable" pain of supply cutoff. At the level of "whether the growth model is healthy and sustainable and whether it relies on harming society and regulation," CHD is a rare high scorer: its growth relies on the real repeat purchase of everyday necessities, stepping into no gray zone of regulatory or social controversy, and this "clean growth" is part of its quality character.

  First, "indispensability"—this question calls for honesty: CHD is "will be missed, but can be replaced":

  • The brands have real mindshare, and their absence would feel awkward. ARM & HAMMER is a national-level flagship brand, disclosed in its 2024 annual report to reach about 86% of U.S. households; TheraBreath (oral care), Hero (acne care), Batiste (dry shampoo), and Touchland (hand sanitizer) are all high-awareness, high-repeat brands in their subcategories. Consumers have habit and trust for these products, forming what the report calls a "soft switching cost."
  • But nearly every category has an equivalent substitute. The rivals the company itself lists are giants such as P&G, Clorox, Colgate-Palmolive, and Reckitt; categories like laundry, oral care, and cleaning never lack substitutes on the shelf. More telling: even the customers themselves are making substitutes—the 10-K states plainly that in 2025 some of the company's largest customers launched private labels competing with its products. So the "missing" is at the brand level, not functional irreplaceability.
  • No lock-in; it relies on habit rather than contract. Revenue comes from product shipments rather than subscriptions/contracts, and consumers can switch brands at any time; it is close to "quasi-recurring" because of high-frequency repeat purchase, not any forced stickiness.

  Next, "whether growth is healthy and whether it harms society and regulation"—the dual premise this chained question requires to be filled in, and also a strength of CHD:

  • Clean growth sources, positive social character. It sells everyday necessities such as laundry, cleaning, oral care, and personal care—real demand, natural repeat purchase, not relying on addictiveness, inducement, or regulatory arbitrage. Management defines 2026 growth as "volume driven," with about half contributed by new-product innovation, rather than aggressive price increases or gray tactics—a sustainable, socially acceptable growth model.
  • Subject to ordinary consumer-goods regulation, but not a high-risk regulated industry. Many of the company's products are regulated by the FDA, EPA, FTC, CPSC, etc., and problems with labeling, ingredients, or advertising carry fine/recall/sales-suspension risk—this is the routine compliance burden of everyday consumer goods, not the structural risk of tobacco, gambling, or usury where "growth itself conflicts with social interest." In other words, regulation is a rule it must follow, not the price of its growth.
  • No sign of trading social harm for growth. From the report's review of its history, the company's growth relies on brand, channel, innovation, and M&A, without relying on any means that would backfire on social trust; this makes its growth "flawless but also without premium" on the ESG and regulatory dimensions.

  Honest conclusion: measured by "how much customers would miss it if it disappeared tomorrow," CHD is moderate—the brands would be missed, but the functions can be replaced, so it is not indispensable; but measured by "whether the growth model is healthy and free of reliance on harming society and regulation," it scores high—clean, necessary, sustainable growth is an important part of its character as a high-quality defensive asset. Putting the two together: this is a good business that reassures you, but that you can live without.

  Jun 11, 2026
• QWhat are this business's unit economics (gross margin, incremental returns)? Does it get better or worse as scale grows? Where does the money it earns go?6/10

  A

  Bottom line up front: CHD's unit economics are quite excellent—high gross margin, light capital, strong cash conversion—and as the portfolio migrates toward high-quality fast-moving consumer brands, the unit economics are improving rather than deteriorating. The money it earns goes mainly in three directions: disciplined M&A (buying high-growth new brands), shareholder returns (dividends + buybacks), and investment in the future (marketing, e-commerce, international). This is the core support for its claim to "high-quality consumer platform" pricing, and the most solid part of the report's judgment.

  First, the absolute level of unit economics—the evidence is hard:

  • High and expanding gross margin. Full-year 2025 adjusted gross margin reached 45.5%, up about 90bp year over year, with 2026 guidance for another expansion of about 100bp. For a mature everyday-goods company, a gross margin above 45% puts it among the top students.
  • Sound operating margin. 2025 reported operating profit of $1.0776 billion against net sales of $6.203 billion, an approximately 17.4% reported operating margin, about 18.9% adjusted.
  • Extremely light capital, extremely strong cash conversion. 2025 capex was only $122.4 million (about 2% of sales), yet it produced $1.215 billion of operating cash flow—meaning growth barely devours capital and most of the profit earned can be converted into real cash. The report notes that from 2019 to 2025 free cash flow was higher than net income in nearly every year, consistent with this. Normalized ROIC is in the mid-double-digit range, a quite respectable return on capital for mature consumer goods.

  Next, "does unit economics get better or worse as scale grows"—the crux of this question, and CHD's answer leans "better":

  Its unit-economics improvement comes from actively swapping the portfolio toward high-margin, high-growth categories, rather than the passive effect of scale dilution. The company divested low-margin businesses such as vitamins, Flawless, and Spinbrush (2025 exits together took away about $400 million in revenue) while folding in higher-margin, faster-turnover fast-moving consumer brands (Touchland, TheraBreath). Management's 2026 guidance explicitly attributes gross-margin expansion to "higher volume, productivity, and favorable mix from acquisitions." In other words, scale + portfolio upgrade jointly push unit economics higher—a healthy "getting better as it grows," rather than the "bigger and blunter" of many giants.

  The only discount to apply is that incremental returns are capped by market size and competition: because its categories are mature and organic growth is only single-digit, the unit economics are good, but the high-return increments it can invest in are inherently limited—which is why a large amount of cash goes to buybacks and dividends rather than all being reinvested in expansion.

  Finally, "where the money goes"—three clear destinations:

  • Acquiring new water sources: Touchland ($700 million plus up to $180 million earnout) and the early-2026 TheraBreath-related acquisition are the money for "small, frequent bolt-on M&A."
  • Shareholder returns: in 2025 repurchased about $900 million, and in 2026 raised the dividend by 4%, to about $291 million.
  • Investing in the future: in 2026 marketing exceeds 11% of sales and SG&A share rises to support e-commerce and international.

  One point to guard against: the "quality" of the buybacks is discounted—the $900 million of 2025 buybacks happened at a P/E above 30x, looking more like routine buybacks than bottom-fishing at undervaluation, which lowers the value-creation efficiency of this portion of capital.

  Honest conclusion: unit economics are CHD's strongest side—high gross margin, light capital, strong cash, and getting better with portfolio upgrades, a real and verifiable strength; the money's destinations are also rational (M&A + returns + investing in the future). The only marks off are that incremental-reinvestment room is capped by the mature market and buyback timing is not shrewd enough. On balance, CHD deservedly scores high on this question.

  Jun 11, 2026
• QWhat conditions would all have to hold for it to rise five-fold in ten years? Are these conditions realistic? What expectations does today's share price imply?2/10

  A

  Bottom line up front: the conditions required for CHD to rise five-fold in ten years, stacked together, are near-impossible—this is its hardest negative in the Baillie Gifford framework. Five-fold in ten years implies about 17.5% annualized total return; but the company's current free-cash-flow yield is only about 4.6%–4.7% (per the report's estimate), organic-growth guidance is just 3%–4%, and the valuation is already at a high P/E of about 32x. Putting these together, a five-fold return requires "the company vastly exceeding expectations + the valuation expanding sharply again" to happen simultaneously, rather than merely "the company getting better"—and neither is in the reasonable base case.

  First, break down "what conditions must all hold for five-fold in ten years," checking each against reality:

  • Condition one: earnings growth doubles to double digits and holds for ten years. If five-fold is driven mainly by earnings (valuation unchanged), it needs about 17% annualized EPS growth. Reality: the company's 2025 adjusted EPS was only +2.6%, 2026 guidance is adjusted EPS +5%–8%, and the past six years' revenue CAGR was about 6%. Jumping from 6% to 17% and holding it for ten years would mean building another company—unrealistic.
  • Condition two: the valuation expands sharply again from an already-high level. If earnings grow mid-single-digit and the valuation must make up the rest to five-fold, the P/E would have to expand from 32x to 60–70x—absurd for a mature consumer-goods company, and the downside risk is greater instead (per the report, as of May 22, 2026 the S&P 500 forward P/E was about 22.5x, and CHD is already significantly above the market).
  • Condition three: M&A keeps succeeding without stepping on a mine. The second curve depends heavily on continually buying right and integrating well new brands (Touchland, TheraBreath); any overpayment or integration failure would backfire (the 2024 $357.1 million trade-name impairment of the vitamins business is a cautionary precedent). Contributing large increments through M&A with zero mistakes over ten years has low probability.
  • Condition four: core categories are not eroded by private labels and channels. But the 10-K makes clear that large customers are pushing private-label competition, and Walmart accounts for 23% and the top four customers 44%; channel and competitive pressure only rise.

  All four must hold simultaneously for five-fold, and at least two of them (doubling growth, re-expanding valuation) directly contradict the company's fundamentals and current pricing. So honestly: five-fold in ten years for CHD is "outside the range of reasonable possibility," rather than merely "challenging."

  Next, "what expectations does today's share price imply"—the key this chained question requires to be filled in, and the most telling:

  The current share price is about $98, market cap about $23.3 billion, P/E about 32x, corresponding to a free-cash-flow yield of only about 4.6%–4.7%, an almost-zero spread over the 10-year Treasury at about 4.55%. This means today's market pricing already implies the optimistic assumptions of "sustained mid-single-digit growth + margin discipline held + no valuation contraction"—the report's owner-earnings discount also shows the current price sits broadly inside the neutral value band (about $88–103 per the report), well above the conservative band (about $60–70 per the report). In other words, the share price has already paid in advance for "high-quality and able to keep delivering," leaving investors a "fairly-to-slightly-expensive, execution-highly-sensitive" position rather than "undervalued five-fold upside." Any outcome that is "just not that good" could trigger a downward re-rating.

  Honest conclusion: the conditions required for five-fold in ten years can hardly all hold at once—this is CHD's fundamental ceiling as a growth name; and today's share price already implies fairly optimistic expectations, with an insufficient margin of safety. For long-term value investors, this means the reasonable expectation is mid-single-digit annualized returns (the report gives 6%–8% for the neutral scenario), rather than a five-fold growth dream—holding it as a high-quality defensive asset is fine, but buying it as the next five-fold-in-ten-years is a misreading of the odds.

  Jun 11, 2026
• QWhy hasn't the market realized all this yet? Is it that it can't understand it, looks down on it, or can't see far enough? What would become the "narrative inflection point"?3/10

  A

  Bottom line up front: for CHD this question must be answered in reverse. Far from "not yet realizing its strengths," the market has already fully, even slightly excessively, realized its strengths, and has priced that recognition into a P/E of about 32x. This Baillie Gifford question is usually prepared for "undervalued great growth stocks," but CHD is not a dust-covered name that is "misunderstood/looked down on/seen too near"; it is a high-quality defensive stock that is seen very clearly and priced very fully. The real perception gap (if any) is only in a very narrow direction, and the narrative inflection point is more likely to be "downward disconfirmation" than "upward discovery."

  Why say the market already understands it, values it, and sees it? Comparing across three dimensions:

  • Can't understand it? Nonexistent. This is an extremely easy business to understand—branded everyday goods, high repeat, low unit price, light capital. Sell-side coverage is ample; the current analyst target price of about $103 is close to the current price of about $98, showing the market has consensus on its value with no understanding gap.
  • Looks down on it? On the contrary, it grants a premium. Far from slighting it, the market instead pays a premium for its quality: 2025 organic growth of only 0.7% and adjusted EPS of only +2.6%, yet it carries a 32x P/E, significantly above the S&P 500 forward P/E of about 22.5x on the report's basis (as of May 22, 2026). This is "valuing it enough to pay a growth premium," rather than "looking down on it."
  • Can't see far enough? The future the market sees is even a bit optimistic. The current free-cash-flow yield is only about 4.6%–4.7% (per the report's estimate), an almost-zero spread over the 10-year Treasury at about 4.55%, meaning the market has already priced in the optimistic scenario of "sustained mid-single-digit growth + margins held + no valuation contraction." The report's discount also shows the current price falls inside the neutral value band (about $88–103 per the report), well above the conservative band—the market has already seen a fairly optimistic distance, rather than seeing too near.

  So what is the real answer to "why hasn't the market realized it yet" for CHD? It is: there is no undiscovered upside perception gap; instead there are overlooked downside risk points. What the market may underestimate is its fragility, rather than its strengths—for example, large customers pushing private labels to erode share, the channel concentration of Walmart at 23% and the top four customers at 44%, and the execution uncertainty from a newly installed CEO and the still-to-be-proven integration of Touchland/TheraBreath. In other words, the direction of the perception gap is downward.

  Finally, "what would become the narrative inflection point"—the key this chained question requires to be filled in. For CHD, the inflection point is more likely a negative trigger than a positive discovery:

  • Downward inflection (more likely): organic growth below the industry for several consecutive quarters, propped up only by price increases; a structural decline in adjusted gross/operating margin; core growth brands (TheraBreath, Hero, Touchland) losing share and unable to cover the gap left by divested businesses; or management making another expensive acquisition in a high-valuation environment, causing goodwill impairment. Any one of these coming true would knock the "high-quality growth premium" narrative back to "an ordinary mature consumer stock," triggering the valuation to revert from 32x toward the market level—the report estimates such a re-rating could bring an about 30%–45% decline (per the report's scenario estimate).
  • Upward inflection (harder): to turn the narrative upward would require Touchland/TheraBreath to keep growing fast and significantly beat expectations, and the international target of $1 billion toward $2 billion to be delivered faster (strategic pillars in the 10-K), thereby proving its growth is steeper than the market thinks. But because the valuation is already high, even if delivered, the upside would very likely be suppressed by the valuation.

  Honest conclusion: CHD is a high-quality defensive asset seen through very clearly and priced very fully, rather than a dust-covered stock misjudged by the market—the framing of "why hasn't the market realized it yet" barely applies to it. What truly deserves watching is vigilance against downward narrative disconfirmation, rather than waiting for upward narrative discovery: once growth or margins show structural weakening, the high premium becomes an amplifier of the decline. This is precisely the core of the report's "good company, price not yet good enough" judgment.

  Jun 11, 2026